Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Luciano J. Costa, Shaji K Kumar, Angela Dispenzieri, Suzanne E. Hayman, Francis K. Buadi, David M Dingli, Mark R Litzow, Morie Gertz, Martha Lacy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) induces graft-versus-myeloma effect and can overcome resistance to conventional therapy but is limited by the risk of graft versus host disease and high transplant-related mortality (TRM). Between 1991 and 2006, 33 patients underwent a myeloablative (52%) or reduced-intensity conditioning (48%) allogeneic HSCT 3.2 months to 15 years after the diagnosis of multiple myeloma (MM). Median overall survival after HSCT was 40.6 months. Twelve patients (36%) are alive, including six patients in Complete response (CR), 8.3 to 172.7 months after HSCT. Patients surviving more than 48 months after transplant were more likely to be younger than 50 (100%vs. 44%, P = 0.017), have received a bone marrow graft (84%vs. 33%, P = 0.033) and less likely to have had prior autologous transplant (0%vs. 56%, P = 0.017). Allogeneic HSCT is feasible in selected patients with MM with adverse disease features and can induced prolonged disease control.

Original languageEnglish (US)
Pages (from-to)781-787
Number of pages7
JournalLeukemia and Lymphoma
Volume50
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Transplants
Autografts
Graft vs Host Disease
Bone Marrow
Survival
Mortality

Keywords

  • Allografts
  • Graft versus host disease
  • Hematopoietic stem cell transplantation
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{64240907134f4f729960ca53a97d1c55,
title = "Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) induces graft-versus-myeloma effect and can overcome resistance to conventional therapy but is limited by the risk of graft versus host disease and high transplant-related mortality (TRM). Between 1991 and 2006, 33 patients underwent a myeloablative (52{\%}) or reduced-intensity conditioning (48{\%}) allogeneic HSCT 3.2 months to 15 years after the diagnosis of multiple myeloma (MM). Median overall survival after HSCT was 40.6 months. Twelve patients (36{\%}) are alive, including six patients in Complete response (CR), 8.3 to 172.7 months after HSCT. Patients surviving more than 48 months after transplant were more likely to be younger than 50 (100{\%}vs. 44{\%}, P = 0.017), have received a bone marrow graft (84{\%}vs. 33{\%}, P = 0.033) and less likely to have had prior autologous transplant (0{\%}vs. 56{\%}, P = 0.017). Allogeneic HSCT is feasible in selected patients with MM with adverse disease features and can induced prolonged disease control.",
keywords = "Allografts, Graft versus host disease, Hematopoietic stem cell transplantation, Multiple myeloma",
author = "Costa, {Luciano J.} and Kumar, {Shaji K} and Angela Dispenzieri and Hayman, {Suzanne E.} and Buadi, {Francis K.} and Dingli, {David M} and Litzow, {Mark R} and Morie Gertz and Martha Lacy",
year = "2009",
doi = "10.1080/10428190902803644",
language = "English (US)",
volume = "50",
pages = "781--787",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma

AU - Costa, Luciano J.

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Hayman, Suzanne E.

AU - Buadi, Francis K.

AU - Dingli, David M

AU - Litzow, Mark R

AU - Gertz, Morie

AU - Lacy, Martha

PY - 2009

Y1 - 2009

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) induces graft-versus-myeloma effect and can overcome resistance to conventional therapy but is limited by the risk of graft versus host disease and high transplant-related mortality (TRM). Between 1991 and 2006, 33 patients underwent a myeloablative (52%) or reduced-intensity conditioning (48%) allogeneic HSCT 3.2 months to 15 years after the diagnosis of multiple myeloma (MM). Median overall survival after HSCT was 40.6 months. Twelve patients (36%) are alive, including six patients in Complete response (CR), 8.3 to 172.7 months after HSCT. Patients surviving more than 48 months after transplant were more likely to be younger than 50 (100%vs. 44%, P = 0.017), have received a bone marrow graft (84%vs. 33%, P = 0.033) and less likely to have had prior autologous transplant (0%vs. 56%, P = 0.017). Allogeneic HSCT is feasible in selected patients with MM with adverse disease features and can induced prolonged disease control.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) induces graft-versus-myeloma effect and can overcome resistance to conventional therapy but is limited by the risk of graft versus host disease and high transplant-related mortality (TRM). Between 1991 and 2006, 33 patients underwent a myeloablative (52%) or reduced-intensity conditioning (48%) allogeneic HSCT 3.2 months to 15 years after the diagnosis of multiple myeloma (MM). Median overall survival after HSCT was 40.6 months. Twelve patients (36%) are alive, including six patients in Complete response (CR), 8.3 to 172.7 months after HSCT. Patients surviving more than 48 months after transplant were more likely to be younger than 50 (100%vs. 44%, P = 0.017), have received a bone marrow graft (84%vs. 33%, P = 0.033) and less likely to have had prior autologous transplant (0%vs. 56%, P = 0.017). Allogeneic HSCT is feasible in selected patients with MM with adverse disease features and can induced prolonged disease control.

KW - Allografts

KW - Graft versus host disease

KW - Hematopoietic stem cell transplantation

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=68449088807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449088807&partnerID=8YFLogxK

U2 - 10.1080/10428190902803644

DO - 10.1080/10428190902803644

M3 - Article

VL - 50

SP - 781

EP - 787

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -